O-cyclopentyl-S-diethylaminoethyl methylphosphonothioate

RN given refers to ((S)-(+))-isomer

Also Known As:

CDAMP; O-cyclopentyl-S-diethylaminoethyl methylphosphonothioate, (R)-(-)-isomer

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphates: 1942
    - Organothiophosphates: 1
      - O-cyclopentyl-S-diethylaminoethyl methylphosphonothioate: 4
  - Organothiophosphorus Compounds
    - Organothiophosphates: 1
      - O-cyclopentyl-S-diethylaminoethyl methylphosphonothioate: 4
- Sulfur Compounds: 278
  - Organothiophosphorus Compounds
    - Organothiophosphates: 1
      - O-cyclopentyl-S-diethylaminoethyl methylphosphonothioate: 4

Experts

1.	Li, Qingqing: 1 article (11/2017)
2.	Ma, Yuting: 1 article (11/2017)
3.	Pitt, Jonathan M: 1 article (11/2017)
4.	Yang, Heng: 1 article (11/2017)
5.	Apetoh, Lionel: 1 article (03/2014)
6.	Aymeric, Laetitia: 1 article (03/2014)
7.	Ghiringhelli, François: 1 article (03/2014)
8.	Hannani, Dalil: 1 article (03/2014)
9.	Kepp, Oliver: 1 article (03/2014)
10.	Kroemer, Guido: 1 article (03/2014)

Related Diseases

1.	Lymphoma (Lymphomas) 01/01/2006 - "In this study, we show that cycloSaligenyl-2-chloro-2 '-deoxyadenosine monophosphate (cycloSal-CdAMP) is 10-fold more potent that CdA in a dCK-deficient lymphoma cell line. "
2.	Neoplasms (Cancer) 11/01/2017 - "This review focuses on immune-modulatory properties of anti-cancer regimens and CDAMP-mediated communications between cell stress responses and the immune contexture of TME. " 03/01/2014 - "Preclinical data revealed that dying tumor cells can emit a series of danger signals (so-called "cell-death-associated molecular patterns" (CDAMP)) that will dictate the recruitment and activation of specific inflammatory phagocytes. " 03/01/2014 - "We discuss here how such CDAMP could serve as predictive biomarkers that could discriminate immunogenic from nonimmunogenic anti-cancer compounds, and, in case of deficiency, could be compensated by surrogate products to ameliorate the success rate of conventional anticancer treatment modalities."
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/01/1998 - "The pharmacokinetic parameters of cladribine (CdA) in patient plasma and its intracellular nucleotides CdA 5'-monophosphate (CdAMP) and CdA 5'-triphosphate (CdATP) were delineated in circulating leukemia cells in 17 patients with chronic lymphocytic leukemia, after the last dose intake and up to 72 h thereafter. "
4.	Leukemia 03/01/1998 - "The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen. " 03/01/1998 - "The pharmacokinetic parameters of cladribine (CdA) in patient plasma and its intracellular nucleotides CdA 5'-monophosphate (CdAMP) and CdA 5'-triphosphate (CdATP) were delineated in circulating leukemia cells in 17 patients with chronic lymphocytic leukemia, after the last dose intake and up to 72 h thereafter. "

Related Drugs and Biologics

1.	2'-deoxy-5'-adenosine monophosphate (deoxyadenosine monophosphate)
2.	Cladribine
3.	Biomarkers (Surrogate Marker)
4.	Nucleotides